Fate Therapeutics Inc (FATE)
3.94
-0.36
(-8.37%)
USD |
NASDAQ |
Apr 25, 10:43
Fate Therapeutics Cash from Investing (Quarterly): 45.35M for Dec. 31, 2023
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 45.35M |
| September 30, 2023 | 24.80M |
| June 30, 2023 | 33.17M |
| March 31, 2023 | 9.34M |
| December 31, 2022 | 53.11M |
| September 30, 2022 | 80.38M |
| June 30, 2022 | 40.29M |
| March 31, 2022 | -7.026M |
| December 31, 2021 | 71.28M |
| September 30, 2021 | 77.96M |
| June 30, 2021 | -1.372M |
| March 31, 2021 | -471.89M |
| December 31, 2020 | -166.03M |
| September 30, 2020 | -54.14M |
| June 30, 2020 | 35.32M |
| March 31, 2020 | 23.77M |
| December 31, 2019 | -110.52M |
| September 30, 2019 | 36.29M |
| June 30, 2019 | -91.98M |
| March 31, 2019 | 8.754M |
| December 31, 2018 | 16.38M |
| September 30, 2018 | 13.28M |
| Date | Value |
|---|---|
| June 30, 2018 | 13.72M |
| March 31, 2018 | -43.84M |
| December 31, 2017 | 13.20M |
| September 30, 2017 | 13.64M |
| June 30, 2017 | 1.339M |
| March 31, 2017 | -38.38M |
| December 31, 2016 | 5.978M |
| September 30, 2016 | 0.458M |
| June 30, 2016 | 5.794M |
| March 31, 2016 | -16.34M |
| December 31, 2015 | -0.178M |
| September 30, 2015 | -0.655M |
| June 30, 2015 | -0.213M |
| March 31, 2015 | -0.452M |
| December 31, 2014 | -0.271M |
| September 30, 2014 | -0.187M |
| June 30, 2014 | -0.026M |
| March 31, 2014 | -0.398M |
| December 31, 2013 | -0.15M |
| September 30, 2013 | -0.017M |
| June 30, 2013 | -0.064M |
| March 31, 2013 | -0.007M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-471.89M
Minimum
Mar 2021
80.38M
Maximum
Sep 2022
-19.57M
Average
24.80M
Median
Sep 2023
Cash from Investing (Quarterly) Benchmarks
| Amicus Therapeutics Inc | -23.96M |
| Regeneron Pharmaceuticals Inc | -66.20M |
| Sarepta Therapeutics Inc | -64.36M |
| ADMA Biologics Inc | -1.407M |
| Ocular Therapeutix Inc | -0.459M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -36.64M |
| Cash from Financing (Quarterly) | -0.18M |
| Free Cash Flow | -138.42M |
| Free Cash Flow Per Share (Quarterly) | -0.3733 |
| Free Cash Flow to Equity (Quarterly) | -36.82M |
| Free Cash Flow Yield | -35.70% |